BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 16619554)

  • 1. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Oncol Rep; 2005 Aug; 14(2):433-9. PubMed ID: 16012727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Glimelius B; Dahl O; Cedermark B; Jakobsen A; Bentzen SM; Starkhammar H; Grönberg H; Hultborn R; Albertsson M; Påhlman L; Tveit KM;
    Acta Oncol; 2005; 44(8):904-12. PubMed ID: 16332600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
    Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
    Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
    J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
    J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer.
    Ito I; Mukai M; Ninomiya H; Kishima K; Tsuchiya K; Tajima T; Oida Y; Nakamura M; Makuuchi H
    Oncol Rep; 2008 Nov; 20(5):1189-94. PubMed ID: 18949420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
    Thirion P; Piedbois P; Buyse M; O'Dwyer PJ; Cunningham D; Man A; Greco FA; Colucci G; Köhne CH; Di Constanzo F; Piga A; Palmeri S; Dufour P; Cassano A; Pajkos G; Pensel RA; Aykan NF; Marsh J; Seymour MT;
    Br J Cancer; 2001 Mar; 84(5):611-20. PubMed ID: 11237380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
    Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Anticancer Res; 2006; 26(2B):1377-83. PubMed ID: 16619547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy of stage III colon cancer.
    Benson AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S74-7. PubMed ID: 16399437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
    Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
    Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
    Kodaira S; Shatari T; Nozawa K
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2201-8. PubMed ID: 11142163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.